




# Screen for dozens of cancers with one blood draw



Cancers diagnosed with a Galleri Cancer Signal Detected result

## ~70%

of cancer deaths are caused by cancers with no recommended screening<sup>1,2\*</sup>

**But the Galleri® multi-cancer early detection test aims to change that.** With a single blood draw, the test screens for a "fingerprint" of more than 50 cancers.<sup>3</sup> helping your employees be proactive about their health.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test identifies DNA in the bloodstream shed by cancer cells and does not predict future genetic risk for cancer. The test should be used in addition to healthcare provider recommended screening tests.

\*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).

# #1

Employees say the Galleri test is the #1 ranked health benefit<sup>4\*</sup>

# 92%

of employees want to know if they have cancer as early as possible<sup>4\*</sup>

\*Market research conducted by Ipsos Group. Study demographics included 1,000 respondents who were full-time employees working at companies with at least 3,000 employees: 15% of sample ages 65+, 70% of sample ages 50-64, and 15% ages under 50 with cancer risk factors. Respondents were a representative mix across gender, region, race, and ethnicity.



## A breakthrough tool to screen for cancer

Existing recommended cancer screening tests look for cancers one at a time. By adding the Galleri test, you can detect a signal shared by more than 50 types of cancer, and can predict the tissue type or organ associated with the cancer signal.<sup>3</sup> All it takes is a simple blood draw.

## Cancer's effect on employee health

Cancer has a significant impact on employees' physical health. But it also affects their mental health, financial well-being, and makes existing health equity disparities worse. The Galleri test could help.

The Galleri test should be used in addition to healthcare provider recommended screening tests.

### PHYSICAL HEALTH

#### STATUS QUO

About 70% of cancer deaths are caused by cancers with **no** recommended screening tests.<sup>1,5\*</sup>

#### WITH THE GALLERI TEST

Based on modeled data, adding the Galleri test to usual care has the potential to shift cancer detection to earlier stages, showing a **26% reduction in deaths.**<sup>6†</sup>

### MENTAL HEALTH

#### STATUS QUO

Cancer is the #1 ranked medical fear for Americans.<sup>7</sup>

#### WITH THE GALLERI TEST

76% of market research respondents agree that "receiving a No Cancer Signal Detected result would **help to address one of their top health anxieties.**"<sup>4,10‡§</sup>

### FINANCIAL HEALTH

#### STATUS QUO

Cancer is the #1 cost driver for employers,<sup>8</sup> also leading to significant out-of-pocket costs for employees.<sup>9</sup>

#### WITH THE GALLERI TEST

Based on modeled data, adding the Galleri test to usual care has the potential to shift 50% of late-stage cancers to earlier stages, potentially resulting in a **24% reduction in direct medical spending** on members with metastatic diagnoses.<sup>6</sup>

\*Assumes screening is available for all colorectal, breast, prostate, cervical cancer cases, and 43% of lung cancer cases (based on the estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years). †Modeled data of early version of the Galleri test added to usual care in elevated risk population ages 50-79 years. Usual care includes screening, incidental detection, and symptomatic workup. ‡Anxiety was evaluated in the PATHFINDER study. Mean general anxiety scores increased in all groups following Return of Results (RoR), remained increased at diagnostic resolution (in cancer-confirmed group), and trended towards baseline by 12-month end-of-study assessment. The proportion of participants with clinically meaningful increase in general anxiety was highest in those who were true positive.<sup>10</sup> Individual results may vary. A survey of 1,000 employees at elevated risk for cancer (ages 50+ or 35-49 at high risk) working at medium to large US companies (of 3,000+ employees). §% Selecting Somewhat or Strongly Agree, 5-point scale. Base: All respondents (n=1000) receiving a No Cancer Signal Detected result would help to address one of my top health anxieties.<sup>4</sup>

### HEALTH EQUITY

#### STATUS QUO

Data shows that cancer worsens existing racial/ethnic, geographic, and socioeconomic disparities.<sup>1</sup>

#### WITH GALLERI

**The Galleri test provides equitable access for employees through just one blood draw, available almost anywhere.**

This is included as part of the test, via workplace events, home visits, and 6,600+ partner labs nationwide.

**Just 1 blood draw,  
available almost anywhere**

**Community**  
(6,600 Quest labs nationwide)

**Workplace**  
(Blood draw event or on-site clinic)

**Home**  
(A house visit from a phlebotomist)



## How the Galleri test works

All cells, healthy and cancerous, release DNA into the bloodstream. But DNA from cancer cells is different from DNA from healthy cells. Using next-generation DNA sequencing, machine learning, and AI, the Galleri test can detect a cancer signal in the blood and predict the tissue or organ associated with the cancer signal.

### DEPENDABLE

**0.5%**  
false positive  
rate<sup>3</sup>

(found in study participants without cancer)

### ACTIONABLE

**93.4%**  
accuracy<sup>11</sup>

(in predicting cancer signal origin,  
found in study participants with cancer)

### IMPACTFUL

**76.3%**  
sensitivity<sup>3</sup>

(in 12 deadly cancers (51.5% overall sensitivity))<sup>3</sup>

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests.

In the Circulating Cell-free Genome Atlas substudy (CCGA3), a prospective, case-controlled, observational study that included cancer (n = 2823) and noncancer (n = 1254) participants without a history of cancer.

\*The group of cancers responsible for two-thirds of annual US cancer deaths included anus, bladder, colon/rectum, esophagus, head and neck, liver/bile-duct, lung, lymphoma, ovary, pancreas, plasma cell neoplasm, and stomach.

## A comprehensive and employee-oriented experience

From helping eligible employees schedule their blood draw to follow-up consultations after they get results, the Galleri test experience is designed to support employees at each step:



1

**Awareness  
and education**  
with customized  
materials



2

**Online test  
request, followed by  
in-person blood draw**  
(test requires  
a prescription)



3

**Return of results**  
to provider within  
10 business days of  
receipt at GRAIL lab



4

**Support services for  
positive test results**  
in the event a cancer  
signal is detected

The Galleri test was studied in clinical studies across 20+ clinical study institutions, including:



*"I really appreciate the company's interest in employees' ... well-being ... [demonstrating] ... that employees are people and not just resources."*

—Employee (Galleri program participant)



Contact us to find out more about the **Galleri test** and the comprehensive marketing campaigns and support to integrate this benefit into your organization.



[Galleri.com/employers](https://galleri.com/employers)



[employer@grailbio.com](mailto:employer@grailbio.com)

#### Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. **Rx only.**

#### Laboratory/Test Information

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

#### References

1. American Cancer Society. Cancer facts & figures 2022. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html> [GRAIL, Inc. Data on file: GA-2021-0065]
2. Surveillance, Epidemiology, and End Results (SEER) Program SEER\*Stat Database: Incidence - SEER 18 Regs Research Data, 2017 Nov Sub. Includes persons aged 50+ diagnosed 2006-2015.
3. Klein EA, et al. Ann Oncol. 2021;32(9):1167-77.
4. Ipsos market research. [GRAIL, Inc. Data on file: GA-2023-0102]
5. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2025 Mar 18]. [https://www.uspreventiveservicestaskforce.org/uspstf/topic\\_search\\_results](https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results)
6. Hubbell E, et al. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460-468.
7. Barker AD, Jordan H. Public Attitudes Concerning Cancer. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. [https://www.ncbi.nlm.nih.gov/books/NBK13445/Business Group on Health. 2023 Large employers' health care strategy and plan design survey. 2022 Aug. <https://www.businessgrouphealth.org/resources/2023-large-employers-health-care-strategy-survey-intro>](https://www.ncbi.nlm.nih.gov/books/NBK13445/Business_Group_on_Health_2023_Large_employers'_health_care_strategy_and_plan_design_survey_2022_Aug)
8. American Cancer Society Cancer Action Network. The costs of cancer 2020. <https://www.fightcancer.org/sites/default/files/National%20Documents/Costs-of-Cancer-2020-10222020.pdf>
9. Schrag D, et al. Ann Oncol 2022;33:S963.
10. Schrag, Deb et al. "Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study." Lancet (London, England) vol. 402,10409 (2023): 1251-1260. doi:10.1016/S0140-6736(23)01700-2
11. Enhanced Cancer Signal Origin prediction. [GRAIL, Inc. Data on file: VV-TMF-59592]